Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Takeda Pharmaceutical Company Limited    4502   JP3463000004

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Tokyo Stock Exchange
08/03/2020 08/04/2020 08/05/2020 08/06/2020 08/07/2020 Date
3891 3902 3908 3857 3807 Last
4954500 3414100 2546400 2265200 3395000 Volume
+3.59% +0.28% +0.15% -1.31% -1.30% Change
Financials
Sales 2021 3 275 B 30 932 M 30 932 M
Net income 2021 162 B 1 526 M 1 526 M
Net Debt 2021 3 880 B 36 646 M 36 646 M
P/E ratio 2021 59,2x
Yield 2021 4,73%
Sales 2022 3 362 B 31 750 M 31 750 M
Net income 2022 417 B 3 939 M 3 939 M
Net Debt 2022 3 226 B 30 463 M 30 463 M
P/E ratio 2022 14,4x
Yield 2022 4,73%
Capitalization 5 951 B 56 396 M 56 199 M
EV / Sales 2021 3,00x
EV / Sales 2022 2,73x
Nbr of Employees 47 495
Free-Float 98,7%
More Financials
Company
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. Net sales break down by by source of revenue as follows: - sales of drugs and consumer care products (96.6%); - royalties and sales of services (3.4%). Net sales are distributed... 
More about the company
Surperformance© ratings of Takeda Pharmaceutical Comp
Trading Rating : Investor Rating :
More Ratings
Latest news on TAKEDA PHARMACEUTICAL COMP
11:18aPfizer to Manufacture Gilead's Remdesivir for Covid-19 Treatment
DJ
08:25aTAKEDA PHARMACEUTICAL : to supply Novavax's coronavirus vaccine candidate in Jap..
AQ
06:20aJapan in deals with AstraZeneca, Novavax for COVID-19 vaccines
RE
06:13aJapan in deals with AstraZeneca, Novavax for COVID-19 vaccines
RE
06:11aTAKEDA PHARMACEUTICAL : to make Novavax's COVID-19 vaccine candidate in Japan
RE
06:02aJapan in deals with AstraZeneca, Novavax for COVID-19 vaccines
RE
05:35aTAKEDA PHARMACEUTICAL : & Novavax Announce Collaboration For Novavax' COVID-19 V..
RE
05:09aTAKEDA PHARMACEUTICAL : Novavax and Takeda Announce Collaboration for Novavax' C..
PU
05:04aTAKEDA PHARMACEUTICAL : Novavax and Takeda Announce Collaboration for Novavax' C..
PU
08/06TAKEDA PHARMACEUTICAL : BioLife Plasma Services Announces Opening of First Plasm..
BU
08/03TAKEDA PHARMACEUTICAL : Announces FY2020 Q1 Results, Confirms Management Guidanc..
AQ
08/03TAKEDA PHARMACEUTICAL : Notice of the Revised Forecast of Consolidated Financial..
AQ
08/03TAKEDA PHARMACEUTICAL : Announces Support for People Affected by 2020 Torrential..
AQ
08/03Rival drugmakers launch joint trial of medicines for COVID-19
RE
08/03TAKEDA PHARMACEUTICAL : Announcement of a merger (simple merger/short-form merge..
PU
More news
News in other languages on TAKEDA PHARMACEUTICAL COMP
11:18aPfizer to Manufacture Gilead's Remdesivir for Covid-19 Treatment
08:25aTAKEDA PHARMACEUTICAL : to supply Novavax's coronavirus vaccine candidate in Jap..
08:23aCORONAVIRUS : Takeda achète les droits pour le Japon d'un vaccin expérimental
08:22aCORONAVIRUS : Takeda rachète les droits pour le Japon d'un vaccin
06:20aJapan in deals with AstraZeneca, Novavax for COVID-19 vaccines
More news
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMP
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Average target price 5 420,77 JPY
Last Close Price 3 807,00 JPY
Spread / Highest target 70,7%
Spread / Average Target 42,4%
Spread / Lowest Target 7,70%
EPS Revisions
Managers
NameTitle
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Yasuhiko Yamanaka Director
Masato Iwasaki Director & President-Japan Pharma Business Unit
Sector and Competitors
1st jan.Capitalization (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-12.12%57 137
JOHNSON & JOHNSON1.73%388 473
ROCHE HOLDING AG0.33%295 798
PFIZER, INC.-2.32%212 583
MERCK & CO., INC.-10.89%204 995
NOVARTIS AG-17.29%183 979